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Research
A randomized control trial of intensive
aphasia therapy after acute stroke: The
Very Early Rehabilitation for SpEech
(VERSE) study
Erin Godecke1,2 , Elizabeth Armstrong1 , Tapan Rai3,
Natalie Ciccone1 , Miranda L Rose4 , Sandy Middleton5 ,
Anne Whitworth6, Audrey Holland7, Fiona Ellery8,
Graeme J Hankey9, Dominique A Cadilhac10 and Julie Bernhardt8 ;
and on behalf of the VERSE Collaborative Group
Abstract
Background: Effectiveness of early intensive aphasia rehabilitation after stroke is unknown. The Very Early
Rehabilitation for SpEech trial (VERSE) aimed to determine whether intensive aphasia therapy, beginning within
14 days after stroke, improved communication recovery compared to usual care.
Methods: Prospective, randomized, single-blinded trial conducted at 17 acute-care hospitals across Australia/
New Zealand from 2014 to 2018. Participants with aphasia following acute stroke were randomized to receive usual
care (direct usual care aphasia therapy), or one of two higher intensity regimens (20 sessions of either non-prescribed
(usual care-plus or prescribed (VERSE) direct aphasia therapy). The primary outcome was improvement of communi-
cation on the Western Aphasia Battery-Revised Aphasia Quotient (AQ) at 12 weeks after stroke. Our pre-planned
intention to treat analysis combined high intensity groups for the primary outcome.
Findings: Among 13,654 acute stroke patients screened, 25% (3477) had aphasia, of whom 25% (866) were eligible and
246 randomized to usual care (n¼ 81; 33%), usual care-plus (n¼ 82; 33%) or VERSE (n¼ 83; 34%). At 12 weeks after
stroke, the primary outcome was assessed in 217 participants (88%); 14 had died, 9 had withdrawn, and 6 were too
unwell for assessment. Communication recovery was 50.3% (95% CI 45.7–54.8) in the high intensity group (n¼ 147) and
52.1% (95% CI 46.1–58.1) in the usual care group (n¼ 70; difference 1.8, 95% CI 8.7–5.0). There was no difference
between groups in non-fatal or fatal adverse events (p¼ 0.72).
Interpretation: Early, intensive aphasia therapy did not improve communication recovery within 12 weeks post stroke
compared to usual care.
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Evidence before this study
The 2016 Cochrane review1 indicates that aphasia ther-
apy is effective for chronic language/communication
recovery. There is no Level 1 evidence for the effective-
ness of aphasia treatments started within the first two
weeks post stroke when the proposed ‘window of
opportunity’2 for enhanced neuronal recovery is at its
peak. The few studies which commenced treatment
within the first 15 days post stroke have mixed find-
ings;3–5 the most recent study (Rotterdam Aphasia
Therapy Study-3 (RATS-3))3 suggested that early inter-
vention is no better than starting therapy after the first
month post stroke.
Added value of this study
VERSE6 is the first international aphasia trial, which
recruited from 17 acute hospitals. VERSE participants
were followed up at 45 subacute and community
healthcare centers to six months post stroke. VERSE
will contribute to Level 1 evidence about the effective-
ness of intensive early aphasia therapy compared to
usual care in a broad population of acute aphasic
stroke patients. Very early intensive, aphasia therapy
during the hypothesized optimal recovery window2
had no additional benefit to language impairment, dis-
course/connected speech, quality of life, or depression
at 12 or 26 weeks post stroke to usual care. Critically,
there was a large increase in amount of aphasia therapy
in this trial (9.5 h up from a total of 14min) compared
to our earlier pilot study5, which looked promising.
Our findings are in line with those of the A Very
Early Rehabilitation Trial (AVERT)7 whereby an
increase in the intensity of ‘usual care’ services from
pilot studies to the main study was reported and the
Phase III trial was subsequently negative. Taken
together with the AVERT7 results, VERSE provides a
useful guide for the design and analysis of future stroke
rehabilitation RCTs in early stroke recovery.
Background
Aphasia (language impairment affecting spoken lan-
guage, comprehension, reading and writing) is not
rare, affecting approximately one in three8 of the 16.9
million people worldwide who experience stroke each
year.9 People with aphasia have greater mortality and
morbidity, lower levels of social participation and
return-to-work rates, and an almost three-fold greater
risk of experiencing depression than stroke survivors
without aphasia.10 The recent global estimates of
post-stroke aphasia burden in relation to annual dis-
ease costs are AUD$49.3 billion11 ($34.4b USD).
Restorative and compensatory rehabilitation deliv-
ered by speech pathologists is the mainstay of treatment
for aphasia. There are no animal equivalent basic sci-
ence models to drive aphasia recovery research. The
theoretical constructs that underpin aphasia research
derive from an integration of cognitive and motor the-
oretical domains, and extrapolation is required to
explain language recovery. Evidence from human
motor and animal stroke recovery models suggests the
first 90 days post stroke is the ‘window of opportunity’2
where the greatest potential to harness spontaneous
recovery exists.12 This theory suggests that high fre-
quency repetition should strengthen neural networks
and minimize independent neuronal activation,
potentially reducing maladaptive behaviors.2,12
Neurorecovery therapeutic principles guide rehabilita-
tion research and aim to strengthen interaction within
and between neural networks and to promote improved
accuracy and efficiency of function.2,12 Efficacy of
aphasia therapy for functional communication was
established in the Cochrane review (27 randomized
trials including 1620 patients)1 and supported by a
recent European trial13 which showed the benefit of
intensive aphasia therapy in chronic recovery. The
trial provided 10 h of direct therapy per week for
three weeks for a total of 31 (median) h with an add-
itional 15 h (total) of home practice.
Currently, there is no Level I evidence that directly
addresses the timing, intensity, and type of aphasia
therapy, commencing within the first two weeks post
stroke.1 Mixed results are noted from various studies3–5
comparing treatment intensity when intervention was
commenced within two weeks post stroke. Laska
et al.4 (N¼ 123) reported no benefit in speech produc-
tion and comprehension (Norsk Grunntest for Afasi14)
or in functional communication (Amsterdam–
Nijmegen Everyday Language Test15) after 15 h of a
comprehension-based intervention across three weeks,
when compared to no therapy. Our Phase I pilot study5
(N¼ 59) indicated a statistical and clinical benefit from
daily intensive therapy targeted at spoken language.
Over a mean of 19 days, 7.5 h of therapy (or 2.7 h per
week) was compared to standard care (on average <1 h
in total). Language and communication benefits were
observed at therapy completion and six months post
stroke on the Western Aphasia Battery-Revised16 and
the Functional Communication Profile.17 The more
recent RATS-3 trial3 (N¼ 153) demonstrated no benefit
of early therapy consisting of 24.5 h over four weeks
(6.1 h per week) when compared to no therapy in the
first month, measured at 4, 12, and 26 weeks post
stroke. However, only 29% of the intervention group
complied with the prescribed treatment dose of 28 h of
direct aphasia therapy. The ‘per-protocol’ analysis of
the RATS-3 trial3 identified benefit of early treatment
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compared to no treatment at four weeks post stroke, on
measures of spoken language. Our Phase II pilot trial18
(N¼ 20) that was designed to investigate the effect of
treatment type received in early aphasia recovery
(group therapy vs. individual therapy), for 20 h pro-
vided over four weeks (5 h per week), which is at the
lower intensity range found to be effective.19 The trial
found no between-group difference.
While there is no Level 1 evidence for the effective-
ness of very early aphasia therapy, similar research had
been completed in the area of physical rehabilitation
through the AVERT trial.7
The uncertainty around the timing, intensity, and
type of aphasia therapy in the very early stroke recov-
ery window (commencing therapy before day 15 post
stroke) prompted the VERSE trial.6,20 Our primary
hypothesis was that compared to usual care alone
(UC), higher dose early aphasia therapy would result
in improved language and communication at 12 weeks
post stroke, measured by the Western Aphasia Battery-
Revised16 (primary outcome) and discourse analysis21
(secondary outcome). To explore the question of ther-
apy type, the higher dose therapy could be delivered in
one of two ways (UC-Plus and VERSE ther-
apy—outlined below). We further hypothesized that
higher dose training would result in better quality of
life, and be cost effective. This article reports primary
and key secondary outcomes for the trial.
Methods
Study design
A phase three, multicenter, randomized controlled trial,
with allocation 1:2 (UC: UC-Plus and VERSE) and
blinded outcomes assessed at 12 (primary outcome)
and 26 weeks post stroke. The trial protocol6 and stat-
istical analysis plan (SAP)20 were accepted for publica-
tion before unblinding (see Supplement and
publications for full trial methodology description).
The trial was approved by hospital ethics committees
and all participants gave written informed consent
using aphasia friendly consent processes.22
Participants
Participants required the capacity to consent to be eli-
gible and were recruited from 17 acute-care hospitals in
Australia and New Zealand and then followed up at 45
subacute and community healthcare centers.
Eligibility criteria
Participants were aged over 18 years and admitted to
hospital with an acute stroke, resultant acute aphasia of
any type, within 14 days of stroke onset. They required
a score of less than 93.7 on the Aphasia Quotient of the
Revised Western Aphasia Battery (WAB-R AQ)16 indi-
cating mild to severe aphasia. They were medically
stable, could maintain a wakeful alert state for at
least 30min, and had normal or corrected hearing
and vision. Exclusion criteria were pre-existing aphasia
and dementia, a concurrent progressive neurological
disorder, any head injury, neurosurgery, clinical depres-
sion at admission, inability to participate in English-
based therapy, or participation in other concurrent
intervention trials.
Qualified speech pathologists trained to screen and
consent participants, diagnosed aphasia using the
Frenchay Aphasia Screening Test,23 and enrolled eli-
gible participants.
Randomization and masking
Baseline assessments were completed by trained staff
before randomizing participants using a computer-gen-
erated, block randomization sequence (permutated
block of six, with 1:1:1 randomization to three groups
(UC, UC-Plus, VERSE) to achieve an overall ratio of
1:2 (UC; high intensity therapy, combined UC-Plus and
VERSE)19 via Research Electronic Data Capture
(REDCapTM).24 Randomization was performed by
the baseline assessor who was not otherwise involved
in the trial and participants were stratified by aphasia
severity determined by the WAB-R (AQ) score.
Participants, family members, ward staff, and outcome
assessors were not informed of group allocation and all
participants and trial staff were asked not to discuss
treatment received. Only UC staff wrote in medical
notes per healthcare standards and all research docu-
mentation was stored separately in a secured location
to avoid unblinding. Blinded outcome assessors were
not involved in participants’ stroke care and were not
permitted to ask participants about treatment received
during follow-up assessments. Only treating therapists
(acute and subacute) were unblinded to treatment
allocation.
Procedures—Treatment intensity and type
All speech pathology services received by participants
up to 26 weeks post stroke were recorded for all
groups.6 Our focus was the recording of direct aphasia
therapy which was defined as ‘treatment designed to
restore language and communication function’ and
could consist of individual or group social and or
impairment-based treatment, social or communication
device training. Education, counseling, goal-setting,
treatment programming, documentation, and consult-
ation were excluded from these analyses.20
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Usual care
Participants randomized to the UC arm constituted the
trial control group. UC aphasia therapy was standard
care at each site and was not controlled for amount,
frequency of sessions, therapy type, or therapist. For
data reporting purposes, we asked UC therapists to
record all aspects of management and to video record
aphasia therapy sessions, although videorecording was
not mandatory.
High intensity therapy regimens
Participants randomized to either of the high intensity
groups (UC-Plus or VERSE) received usual care ther-
apy and had additional aphasia therapy provided by
specially trained therapists. UC-Plus therapy involved
any combination of therapy at the discretion of the
therapist. Participants were prescribed 20 sessions of
45–60min (15–20 h; or 4–5 h per week) of aphasia ther-
apy, commencing before day 15 and completed within
four weeks.16,20 The intensity level for these groups was
chosen in-line with available evidence (5 h per week19)
and demonstrated tolerability.5,18
VERSE treatment was an impairment-based therapy
program (see Supplement; Intervention Protocol),
developed by an aphasia Expert Advisory Committee.
The VERSE intervention prioritized error-free, verbal
communication, encouraging conversation while work-
ing between 50% and 80% accuracy at each goal level
to maintain a therapy challenge point. In both higher
intensity groups, the amount of therapy and the timing
of commencement of intervention were standardised.6
Training, therapy, and assessment fidelity
All treating speech pathologists underwent protocol
training and received procedural training manuals rele-
vant to the arm of therapy they provided. Training
details and treatment manuals are provided in
Appendix 1. Clinical support was given by central
research staff for UC-Plus therapists, and a VERSE
Therapy Coordinator provided feedback and support
for VERSE therapists. UC-Plus and VERSE therapists
were allocated to a therapy group from a therapist
recruitment pool, depending on trial needs. Therapists
providing UC-Plus and VERSE intervention groups
were mandated to video record a therapy session each
week and submit this to an independent therapy integ-
rity monitor for review and verification (see
Supplement—Main and Intervention Protocols). All
data discrepancies were queried by the Monitor with
clinical staff and all queries resolved prior to database
lock in compliance with all elements of the TIDiER25
and SPIRIT26 statements.
Outcomes
The trial SAP20 outlines the primary and secondary
outcomes in detail. Our primary outcome was improve-
ment in communication at 12 weeks after stroke, mea-
sured by the WAB-R AQ which is a sensitive, valid and
reliable measure of aphasia performance with a stand-
ard error of measurement of 3 points.27 Improvement
was assessed using the percent of maximal potential
recovery achieved (%MPR).28 The %MPR represents
a percentage score of the maximum potential change
(i.e. the endpoint score minus the baseline score) allow-
ing for direct meaningful comparison of amount of pos-
sible improvement on the WAB-R AQ for people with
varied aphasia severity. Using the %MPR also
accounts for the ceiling effects of the standardized
test. All raw scores are presented in Supplemental
Table S3. Based on benchmarking of aphasia interven-
tion studies, a 5-point change on the WAB-R AQ rep-
resents a conservative, clinically meaningful effect.29
Secondary outcomes were: treatment effectiveness
(both %MPR and discourse measures20) at 26 weeks,
word naming (Boston Naming Test30), quality of life
(Stroke and Aphasia Quality of Life scale-3931), depres-
sion (Aphasia Depression Rating Scale32) at 12 and 26
weeks. The Aphasia Depression Rating Scale was com-
pleted by the participant with communication support
from the blinded assessor. Safety (adverse and serious
adverse events) was assessed at 12 and 26 weeks post
stroke. Adverse event reporting followed a protocol,20
an independent medical officer adjudicated events, and
reported to the Data Safety and Monitoring Board.
Statistical analysis
The trial was powered (80% power, 5% significance
level) to detect a between-group difference (UC vs.
high intensity groups) of 20% on %MPR (primary)
at 12 weeks. Adjusting for expected 20% (high level)
lost to follow-up, a total of 246 participants was
planned.20 This was also sufficient to detect a 4.4%
between-group difference (UC-Plus compared to
VERSE) on the %MPR. Using an intention-to-treat
basis, our primary analysis compared higher intensity
therapy (UC-Plus and VERSE groups combined) to
UC on the %MPR on the WAB-R AQ at 12 weeks
post stroke using a linear mixed model which controlled
for baseline WAB-R AQ and baseline National
Institute of Health Stroke Scale (NIHSS)33 as fixed
effects and hospital site as a random effect.20
Unadjusted results for both primary and secondary
analyses are also reported. Safety analyses are reported
in Table 1.
The primary and secondary outcome analyses are
reported without imputation of missing data,20
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supplemented by analyses with imputed data sets (see
Supplement p. 7—Imputation Plot).20 An additional
efficacy subgroup analysis explored age, sex, baseline
aphasia severity (AQ), and disability (mRS34).
Subgroup analysis of treatment type (UC-Plus com-
pared to VERSE subgroup comparisons) used a
linear mixed model (see Supplemental Table S2). No
adjustments were made to p values for multiple com-
parisons in subgroup analyses or the analyses of sec-
ondary outcomes. All analyses were completed using
R35 and statistical analyses were performed by the
trial statistician and verified by a statistician blinded
to group allocation. The trial was registered with the
Australian New Zealand Clinical Trials Registry
(ACTRN12613000776707); and Universal Trial
Number (U1111-1145-4130).
Data availability
VERSE individual deidentified participant trial data
(including data dictionary) will be available through
the CATS36 international aphasia data repository.
Results
Between 4 June 2014 and 10 February 2018, 13,654
patients with acute stroke were screened; 3477 (25%)
had aphasia, 866 (25%) of whom were trial eligible, and
246 (28%) participants were enrolled (Figure 1). Last
patient, last visit occurred on 31 July 2018. One
randomized participant withdrew consent; their data
were withdrawn from analysis (N¼ 245). At the pri-
mary endpoint (week 12), 14 (6%) participants had
died, 9 (4%) had withdrawn, and 6 (2.5%) were too
unwell for assessment, leaving 217 (88%; within the
20% lost to follow-up allowance20) participants in the
primary analysis.
Baseline demographic, stroke, and communication
characteristics were balanced across all groups, except
for greater concomitant dysarthria (frequency and
severity) in the UC group (Table 2; see Supplemental
Table S1 for demographics all groups). A third of par-
ticipants were over 80 years and 71% had moderate to
severe aphasia (WAB-R AQ 62.5). Participants were
randomized at median 9 (IQR 5) days after stroke onset
and 224 (91%) participants received therapy within the
first two weeks of stroke (Table 3). As intended, the
high intensity groups received treatment two days ear-
lier than those receiving UC (p¼ 0.008).
The high intensity groups completed 20 sessions
across 32 days (median) and received a total mean
time of 22.7 h (SD 8.4) h of aphasia therapy (average
of 5 h per week). This compared to 9.5 (SD 7.6) mean
hours over 28 (17) days (median, IQR; average of 2.3 h
per week) in the UC group (Table 3). Four (5%) par-
ticipants in the UC group received no aphasia therapy
during the intervention period. Usual care therapists
submitted three of the total 434 (<1%) video recorded
aphasia therapy sessions. Between the end of the pre-
scribed intervention and the primary endpoint at week






p value Odds ratio (95% CI)
No. of adverse events 33 87 p¼ 0.08a 1.62 (0.92–2.89)
No. of deaths (%) 4 (5) 10 (6) p¼ 1b 1.24 (0.34–5.60)
Depression 19 (23.5) 35 (21) p¼ 0.69a 0.88 (0.45–1.76)
Neurological Complications 2 (2.5) 9 (5.5) p¼ 0.35b 2.27 (0.45–22.10)
No. of serious adverse events (%) p¼ 0.11b –
0 68 (84) 121 (73.3) – –
1 12 (14.8) 29 (17.6) – 1.36 (0.62–3.12)
2 1 (1.2) 9 (5.5) – 5.03 (0.67–224.67)
>2 0 (0) 6 (3.6) – 1 [infinite] (064–1)
UC: usual care.
Data are n (%).
aChi-square test.
bFisher’s exact test.
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12, all participants received usual care speech-language
services: participants in the high intensity group
received a mean of 3.3 (SD 6.0) additional hours of
therapy; UC participants received a mean of 2.9 (SD
5.4) additional hours. Limited additional therapy was
provided after week 12 (Table 3). The intensive inter-
vention was delivered per protocol to 82% (n¼ 164) of
those randomized to UC-Plus and VERSE groups
(Supplemental Table S2). Among the 29 participants
who did not receive the full intervention, 22 were due
to death/illness/fatigue or refusal, 6 to intervention
protocol non-adherence, and 1 was due to insufficient
staffing. Table 4 outlines the therapy components of
UC, UC-Plus, and VERSE.
Figure 1. CONSORT study flow diagram.
International Journal of Stroke, 0(0)
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Table 2. Baseline characteristics of the intention-to-treat population
Usual care (n¼ 81) High intensity (n¼ 164)
Recruitment region
Australia (n, %) 75 (93%) 155 (94%)
New Zealand 6 (7%) 10 (6%)
Patient details
Age (mean, SD) 76 (17) 75 (18)
<65 20 (25%) 43 (26%)
65–80 37 (46%) 67 (41%)
>80 24 (30%) 54 (33%)
Sex
Male (n, %) 38 (47%) 84 (51%)
Female (n, %) 43 (53%) 80 (49%)
Pre-morbid history (living arrangements prior to stroke)
Home alone (n, %) 25 (31%) 44 (27%)
Home with other 53 (65%) 115 (70%)
Supported accommodation 0 (0%) 1 (<1%)
Unknown 3 (4%) 4 (3%)
Stroke risk factors
Hypertension (n, %) 42 (52%) 83 (51%)
Ischemic heart disease 18 (22%) 53 (32%)
Atrial fibrillation 25 (31%) 44 (27%)
Hypercholesterolemia 10 (12%) 16 (10%)
Diabetes 9 (11%) 25 (15%)
Current smoker 10 (12%) 18 (11%)
Baseline NIHSS 8 (7) 9 (6)
Oxfordshire Stroke Classification
TACS (n, %) 17 (21%) 35 (21%)
PACS 55 (68%) 110 (67%)
POCS 3 (4%) 6 (4%)
LACS 0 (0%) 0 (0%)
Hemorrhage 6 (7%) 13 (8%)
(continued)
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At 12 weeks post stroke, the unadjusted
mean %MPR of those in the high intensity group
(UC-Plus and VERSE) was 50.5% (SD 32.4) compared
to 52.9% (SD 29.5) in the UC group (Table 5).
Our primary analysis (adjusted) showed recovery at
52.1% for the UC group (95% CI 46.1–58.1) and
50.3% (95% CI 45.7–54.8) for the high intensity
group, after controlling for baseline AQ, NIHSS, and
hospital site. The between-group difference of 1.8
(favoring control; (95% CI 8.7–5.0) was not signifi-
cant (p¼ 0.59; Figure 2; Supplemental Table S3 for all
group comparisons). Multiple imputations for missing
data, assuming the data were missing at random,
showed similar results. Deviations from this assump-
tion were assessed through a sensitivity analysis
(Supplemental Figure S1).
The results were similar across all secondary out-
comes with no statistically significant differences
noted (Table 5). The pre-specified exploratory analysis
of subgroups20 found no statistically significant
differences for any variables (Supplemental Figure
S3). The subgroup comparisons for %MPR at 12
weeks was 52.2% for the VERSE group (95% CI
46.3–58.2) and 48.4% for the UC-Plus group (95%
CI 42.5–54.3; Supplemental Table S3).
By the 26-week follow-up, 202 participants (82%),
consisting of 139 (85%) participants from the high
intensity group (70 (85%) UC-Plus and 69 (83%)
from VERSE) and 63 (78%) participants from the
UC group, were assessed. At this time point, the overall
group mean %MPR was 56.9% (SD 32.2).
The high intensity group %MPR was 54.7% (SD
34.6) and the UC %MPR was 61.7% (SD 25.8) indicat-
ing greater recovery for usual care participants, though
not statistically significant (p¼ 0.12). There were no
significant differences in non-fatal or fatal adverse
events between groups (Table 1). New cases of depres-
sion were diagnosed in 35 (21%) participants in the
high intensity group compared with 19 (23.5%) in
UC (p¼ 0.67).
Table 2. Continued
Usual care (n¼ 81) High intensity (n¼ 164)
Time to Randomization (days) 9 (4) 10 (5)
Frenchay Aphasia Screening Test 5 (8) 5 (8)
Western Aphasia Battery-Revised Aphasia Quotient (mean, SD) 42.4 (28.9) 40.5 (27.8)
Mild (93.6–62.6) 25 (31%) 47 (29%)
Moderate (62.5–31.3) 24 (29%) 49 (30%)
Severe (0–31.2) 32 (40%) 68 (41%)
Discourse measures (>200 words; N¼ 229) 22 (27%) 41 (25%)
Number of words 159 (171) 151 (204)
Number correct information units 74 (97) 70 (110)
% correct information units 15.1 (25.7) 14.0 (25.8)
Boston Naming Test (N¼ 242; mean, SD) 15.9 (17.4) 13.2 (16.3)
AusTOMS—dysarthria
No impairment (n, %) 50 (62%) 80 (49%)
Apraxia of speech
No impairment (n, %) 38 (47%) 79 (48%)
Clock drawing/cognition test, median (IQR; N¼ 239) 1 (3.5) 1 (3)
Dysphagia present (n, %) 43 (53%) 89 (54%)
NIHSS: National Institutes of Health Stroke Scale; mRS: modified Rankin Scale; TACS: total anterior circulation stroke; PACS: partial anterior circulation
stroke; POCS: posterior circulation stroke; LACS: lacunar stroke; AusTOMS: Australian Therapy Outcome Measures.
Data are mean (SD), n (%), or median (IQR).
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Discussion
We conducted the largest, multicenter aphasia clinical
trial in stroke to date, assessing the effectiveness of
aphasia therapy in very early post-stroke recovery.
Designed to determine if ‘more intensive aphasia ther-
apy is better’ in the acute post-stroke phase, our early
intensive therapy regimen commenced on average two
days earlier and was delivered more frequently and in a
greater amount than in UC. We found that 22 h (or an
average 5 h per week) of aphasia therapy (regardless of
type) delivered over 32 days, showed no benefit over
9.5 h delivered over 28 days (2.3 h per week) for the
primary outcome WAB-R AQ at 12 weeks post
stroke. That is, more therapy started on or before day
eight post stroke, did not significantly enhance lan-
guage or communication recovery, or global outcomes
such as quality of life or depression at 12 or 26 weeks.
Provision of more intensive therapy did not result in
greater adverse outcomes and was safe and feasible to
deliver. The majority of participants in the VERSE
trial, regardless of group allocation, achieved signifi-
cant, clinically meaningful gains in language recovery.
We believe the trial sample was representative of a typ-
ical population with post-stroke aphasia evidenced by
the severity of stroke and aphasia recruited to this
trial.8 Our 7% recruitment rate is consistent with
recruitment for acute stroke trials.7
Our current findings were unexpected, based on our
pilot studies5,18 which showed significant benefit of
early, intensive aphasia treatment. In addition, we
found a considerable increase in the amount of aphasia
therapy provided as usual care, but not in the type of
therapy provided,37 compared with the results of our
pilot trial.5 Our Phase I trial5 was conducted over 10
years ago, and at this time, among the 15% of partici-
pants who received aphasia therapy, only 14min was
provided in a single session over three weeks. The shift
in usual care service delivery in this trial was evidenced
by 81% of UC participants receiving: (i) early aphasia




(n¼ 164) p value
Median shift, mean difference
or odds ratio (95% CI)
Length of inpatient stay (days) 15 (27) 20.5 (40) p¼ 0.2b Median shift¼ 3.0 (1.0–8.0)
Time to first therapy (days) 10 (8) 8 (6) p¼ 0.008b Median shift¼ 2.0 (1.0–3.0)
Received rtPA treatment 17 (21) 26 (16) p¼ 0.32a OR 1.4 (95% CI: (0.7–2.8))
Received therapy as inpatient 77 (95) 164 (100) p¼ 0.011d OR¼1 [infinite] (1.4–1)
Received therapy within 15 days 64 (79) 160 (98) p< 0.001a OR¼ 10.5 (3.3–44.6)
Trial protocol compliant - 135 (82) p¼ 0.94a OR¼ 0.97 (0.44–2.05)
Number of intervention
days (median (IQR))
28 (17) 32 (7) p¼ 0.019e Median shift¼ 3.0 (0.0001–5)
Number of therapy sessions
(intervention period)
12 (11) 30 (14.2) p< 0.001b Median shift¼ 16.0 (14.0–19.0)
Sessions per week 3.1 (2.7) 6.4 (2.9) p< 0.001b Median shift¼ 2.9 (2.4–3.4)
Length of session (minutes) 37.2 (11.7) 45.3 (8.5) p< 0.001c Mean difference¼ 8.1 (5.1–11.0)
Intervention—total therapy 9.5 (7.6) 22.7 (8.4) p< 0.001c Mean difference¼ 13.2 (11.0–15.3)
Week 12 total therapy amount (hours) 12.4 (10.6) 26.0 (11.1) p< 0.001c Mean difference¼ 13.6 (10.7–16.5)
Week 26 total therapy amount (hours) 15.4 (13.4) 28.7 (14.7) p< 0.001c Mean difference¼ 13.3 (9.6–17.0)
rtPA: recombinant tissue plasminogen activator; UC: usual care.
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therapy within the first 15 days post stroke; (ii) more
frequent sessions (3 per week), and (iii) 9.5 h of aphasia
therapy over 28 days. These changes may reflect a
greater focus on national clinical guidelines38 with rec-
ommendations to increase the amount of aphasia ther-
apy based on expert consensus influenced by early, yet
underpowered trials. They may also reflect the fact that
the sites in this trial were self-selected, hence it may be
that these sites have an increased number of therapists
compared to other sites who did not participate in the
trial. The increase in UC aphasia services may also be
the result of an increased will to ‘do more’ as part of the
trial, a phenomenon known as the ‘Hawthorn Effect’,
secondary to recording and monitoring of these ser-
vices. For the Usual Care therapy sessions, fewer than
1% of sessions were video recorded despite the larger
than expected number of hours of aphasia therapy that
were provided to this group in the trial. We believe the
low number of recorded sessions in this group reflects
standard videorecording practice at these sites.
Results presented here are suggestive of the eco-
nomic ‘law of diminishing returns’ applied within a
medical service delivery model which specifies that
‘‘beyond a certain point, additional inputs produce
smaller and smaller outputs’’39 (p. 371). Our sufficiently
powered trial shows diminishing marginal returns from
the additional aphasia therapy provided in early stroke
recovery. The small difference observed in %MPR
(1.8%) between the UC and high intensity cohorts at
12 weeks post stroke, means a 1.8 point difference
for a profoundly impaired participant with a baseline
WAB-R AQ score of 0 (no verbal output). For a par-
ticipant with a baseline AQ of 40 (average for our trial
and indicative of a participant speaking in two-word
phrases with frequent errors and word-finding difficul-
ties), the between group difference equates to 1.14
points at 12 weeks. These small group differences
were not considered clinically relevant (defined as 5
points29 on the WAB-R AQ).
The within group differences (over 25 points) were
between 50% and 52% of MPR. From a clinical per-
spective, it was reassuring to show the majority of
VERSE participants achieved a large and clinically
meaningful gain in language recovery, regardless of
group allocation, and this was consistent with our ear-
lier trials.5,18 Clinically, the average participant pro-
gressed from speaking in two-word phrases with
multiple word, sound and grammatical errors and
requiring assistance with all communication inter-
actions, to speaking in coherent and appropriate sen-
tences. Prior research to predict maximal potential
aphasia recovery in acute stroke has been limited to
a sample of 21 patients whereby the predicted
improvement within the first 12 weeks was estimated
at 70%.28 Our findings suggest that average predicted
recovery from aphasia at 12 weeks may be some-
what lower than that. However, our findings reflect
considerably more change than expected in people
with chronic aphasia (>6 months post stroke)
where interventions are considered to be potent if
they deliver change of 5-points28 or more on the
WAB-R AQ.
Table 4. Treatment components (type) of usual care, usual care-Plus, and VERSE intervention
Treatment characteristic Usual care Usual care-Plus VERSE
Treatment individually tailored 3 3 3
Treatment included reading and writing 3 3 
Task appropriate for goal/participant 3 3 3
45–60 min direct intervention recorded 3 3 3
Cueing strictly followed hierarchy   3
Successive cues following each error   3
High verbal output by patient /3 /3 3
Reduced verbal output by clinician /3 /3 3
Therapy embedded in conversation /3 /3 3
Verbal output within challenge point /3 /3 3
Salient everyday communication exchanges /3 /3 3
VERSE: Very Early Rehabilitation for SpEech study.
International Journal of Stroke, 0(0)
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The contribution of spontaneous recovery to out-
come remains elusive. Inclusion of a no treatment
arm was not considered ethical in this pragmatic trial,
given that patients in Australia and New Zealand
expect to receive aphasia therapy in the acute phase
of stroke care. It is likely that the early, rapid recovery
in the first six months after stroke seen in this trial is
due to a combination of spontaneous recovery and a
treatment effect. We set about to determine if add-
itional therapy to standard care enhanced spontaneous
recovery rather than attempting to discern the individ-
ual value of each component. In the few studies
where there has been an attempt to measure effects of
spontaneous recovery, varied study designs, small par-
ticipant numbers, different measurement time points, or
different outcome measures have been used, making
the drawing of conclusions problematic. In a meta-
analysis40 of 5928 individual patient data, there are
23 cases5 of documented spontaneous recovery as
part of usual care, that have comparable outcome
measures (completed in English) collected within
14 days (baseline) and 26 weeks post stroke. The
amount of spontaneous language and communication
recovery of this historical control cohort is presented in
the Supplement (Supplemental Figure S4) and indi-
cates a medium effect size well below that seen in the
VERSE trial.
Our results challenge the previously held neuro-
recovery theoretical perception that ‘more intensive
therapy is better’ when commenced in the first two
weeks of stroke onset. The UC therapy regimen of a
mean 9.5 h (SD 7) h, comprising 25- to 45-min sessions
provided three times per week within 38 days (10 days
to randomization and 28 days of intervention) post
stroke may be a sufficient therapy regimen to support
recovery in the first six months post stroke. However,
definitive thresholds regarding timing, intensity and
type of therapy are difficult to describe without stronger
data on natural recovery in the acute phase. Similarly,
while this study provided a higher, more intense dose of
aphasia therapy than is common in early usual care
without significant benefit, it remains unclear whether
a much higher dose, for example, 100 h over 12 weeks,
would be more efficacious.
This study adds strong additional evidence to the
RATS-33 trial findings from an internationally diverse,
English speaking population. RATS-33 showed no sig-
nificant difference between communication recovery at
4, 12 or 26 weeks post stroke after intensive aphasia
therapy in the first six weeks of recovery when com-
pared with a delayed intervention control group. The
VERSE results demonstrate no benefit of intensive
aphasia therapy compared to therapy at a lesser inten-
sity in the first six weeks of language and communica-

























































































































































































































































































































































































































International Journal of Stroke, 0(0)
12 International Journal of Stroke 0(0)
trials3–6 provide compelling evidence to challenge the
‘intensive’ mindset in early stroke language and com-
munication recovery.
The question of ‘what is enough?’ therapy is para-
mount here. Some may propose that the total interven-
tion regimen in this and other trials1,3,4,5,18,40 was
insufficient (below the theoretical threshold of at least
98 h in total19) to demonstrate a benefit of treatment
intensity in this recovery period. We suggest that the
intensity and total hours of intervention in the UC par-
ticipants presented here demonstrate clinically mean-
ingful change that can be attributed to a combination
of therapy effect and spontaneous recovery.
Directions for future early aphasia
therapy research
There is a risk that a ‘non-aphasia expert’ may misin-
terpret the results from this study to indicate that early
aphasia therapy or intensive aphasia therapy does not
lead to meaningful benefits post stroke. This study
addresses the specific issue of ‘more intensive therapy’
in the early recovery period; it did not evaluate chronic
recovery or the effect of ‘treatment’ versus ‘no treat-
ment’. There are several important research areas that
must be addressed in order to deliver improved recov-
ery for people with aphasia. Aphasia research needs
Level 1 evidence to address: (i) the dose response in
early and chronic aphasia recovery; (ii) the optimal
type of therapy to provide to whom and at what time
post stroke; and (iii) what other factors contribute to
early aphasia recovery (e.g. the role of stroke unit care
in clinical improvement). The ability to monitor other
therapies available (i.e. physiotherapy, occupational
therapy) and social interactions was outside the funding
scope of this trial. Within the RCT design, we expect
that the input of other health professionals is similar
across groups. The potential for physical training pro-
vided by other therapists, which may offer additional
language practice, to interact with or support language
recovery is currently unexplored, and may be an area
for future study.
Our results do not support increasing aphasia ther-
apy intensity in the first 38 days post stroke above what
is reported as UC in this trial, nor support the modifi-
cation of existing services related to type and amount of
aphasia therapy provided in current practice in
Australia and New Zealand for post stroke early apha-
sia recovery.
In aphasia research fruitful next important areas of
enquiry should include: (i) strong Phase I studies deter-
mining the effect of a dose range of identified active
ingredients; and (ii) Phase II studies establishing feasi-
bility of dose specific treatment regimens in early apha-
sia recovery.
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